Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma
Mohamed A. Gouda1, Maria A. Zarzour2, Ara A. Vaporciyan3, Kalevi Kairemo4, Hubert H. Chuang4, and Vivek Subbiah1,5
1 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
2 Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
3 Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
4 Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
5 Sarah Cannon Research Institute, Nashville, TN 37203, USA
Correspondence to:
Vivek Subbiah, email: [email protected]
Keywords: pazopanib; precision oncology; sarcoma
Received: June 08, 2023 Accepted: August 21, 2023 Published: September 20, 2023
ABSTRACT
Pazopanib is a multi-kinase inhibitor that is currently approved for treatment of advanced renal cell carcinoma and chemotherapy-refractory soft tissue sarcoma. In this case report, we discuss the case of a patient with a EWSR1-NFATC2 fusion positive bone sarcoma who had exceptional tumor control through using pazopanib and surgery for an overall duration exceeding 5 years. We also review the literature on EWSR1-NFATC2 translocation-associated sarcomas and use of pazopanib in bone sarcomas.
PII: 587
